Evidence map›Paper›PMID 39902101›Full record

ArticlePCN reports : psychiatry and clinical neurosciences2025

Trends in uptake of cancer screening among people with severe mental illness before and after the COVID-19 pandemic in Japan: A repeated cross-sectional study.

Yuto Yamada, Masaki Fujiwara, Naoki Nakaya, Koji Otsuki, Taichi Shimazu, Maiko Fujimori, Shiro Hinotsu, Kiwamu Nagoshi, Yosuke Uchitomi, Masatoshi Inagaki

Abstract read
In one paragraph

Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuto YamadaDepartment of Neuropsychiatry Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan.ORCID 0000-0001-8170-4795
Masaki FujiwaraDepartment of Neuropsychiatry Okayama University Hospital Okayama Japan.ORCID 0000-0002-6181-3166
Naoki NakayaTohoku Medical Megabank Organization Tohoku University Sendai Japan.
Koji OtsukiDepartment of Psychiatry, Faculty of Medicine Shimane University Izumo Japan.ORCID 0000-0002-0980-3614
Taichi ShimazuDivision of Behavioral Sciences National Cancer Center Institute for Cancer Control, National Cancer Center Tokyo Japan.
Maiko FujimoriDivision of Survivorship Research National Cancer Center Institute for Cancer Control, National Cancer Center Tokyo Japan.ORCID 0000-0003-1639-3390
Shiro HinotsuDepartment of Biostatistics and Data Management Sapporo Medical University Sapporo Japan.
Kiwamu NagoshiDepartment of Environmental Medicine and Public Health, Faculty of Medicine Shimane University Izumo Japan.
Yosuke UchitomiDepartment of Cancer Survivorship and Digital Medicine The Jikei University School of Medicine Tokyo Japan.
Masatoshi InagakiDepartment of Psychiatry, Faculty of Medicine Shimane University Izumo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: The aim of this study was to investigate trends in cancer screening participation among people with severe mental illness (PSMI) from periods before and after the COVID-19 pandemic. Methods: In this repeated cross-sectional study, we used anonymized datasets on municipal cancer screening participation among PSMI in Okayama City. The data covered fiscal year (FY) 2018 to FY2022; we used the municipal cancer screening database and Medical Payment for Services and Supports for Persons with Disabilities. PSMI were defined as those with schizophrenia or related psychotic disorders (F20-29) or bipolar disorder (F30 or F31), identified using Results: For all cancer types, cancer screening rates for PSMI in FY2020 (colorectal: 9.0%; lung: 11.6%; gastric: 4.9%; breast: 6.2%; and cervical: 6.1%) were lower than the rates in FY2019 (11.5%, 14.0%, 6.5%, 9.3%, and 8.3%, respectively). In FY2022, the rates (9.9%, 12.9%; 5.3%; 8.0%, and 6.9%, respectively) recovered, but remained low. Conclusion: This study showed that cancer screening rates among PSMI were very low, both before and after the COVID-19 pandemic. Efforts to encourage participation in cancer screening in this population are urgently needed.

Indexed as

bipolar disordercancer screeningCOVID‐19healthcare disparitiesschizophrenia

Identifiers

PMID39902101
PMCPMC11788321

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.